However, the variation in BCL2 positivity was potentially due to the B‐cell lymphoma heterogeneity or the BCL2 mutation altering the immunohistochemical binding site epitope of the antibody. The gene discussed is BCL2; the disease is B-cell non-Hodgkin lymphoma.